- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06041724
Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma
Single-arm II Phase Study of Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Zhiguo Luo, M.D
- Phone Number: 8908 +8621-64175590
- Email: luozhiguo88@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years old, regardless of gender.
- Histology and pathology confirmed advanced mucosal melanoma.
- Gene mutation state is not limited, except BRAFV600 mutation.
- Has not received first-line treatment for advanced melanoma, and temozolomide and cisplatin have been used in the adjuvant therapy phase, except that the adjuvant therapy phase has been over 6 months or more.
- Eastern Cancer Cooperation Group (ECOG) physical condition score (PS) 0-1.
- The estimated survival time is more than 3 months.
- Within 7 days before screening (including 7 days), the laboratory data were required as follows: neutrophil count ≥ 1.5 × 109 shock L, platelet count ≥ 90 × 109 shock L, hemoglobin ≥ 90g/L (no blood transfusion within 14 days), serum total bilirubin ≤ 1.25x normal upper limit (ULN), ALT and AST ≤ 2.5xULN (patients with liver metastasis ≤ 5xULN); serum creatinine ≤ 1.25xULN.
- Have at least one measurable focus (RECIST1.1 standard).
- Subjects (or their legal representatives / guardians) must sign an informed consent form indicating that they understand the purpose of the study, understand the necessary procedures for the study, and are willing to participate in the study.
Exclusion Criteria:
- Patients who have previously used PD-L1 inhibitors, except those who progressed 1 year after the end of adjuvant therapy of PD-L1 monoclonal antibody;
- Allergic to Envafolimab or recombinant human endostatin and experimental chemotherapeutic drugs;
- Received any experimental drugs or antineoplastic drugs within 4 weeks before entering the group;
- There is a risk of bleeding, bleeding events of clinical significance or other taboos in the use of antivascular drugs;
- There is a history of other tumors in the past five years, except for cured cervical cancer or skin basal cell carcinoma;
- There are tumor emergencies that require immediate radiotherapy, such as symptomatic brain or meningeal metastasis, bone-related events, etc;
- Pregnant or lactating women; Fertile women who do not use adequate contraception;
- Alcohol or drug addiction;
- Patients with active, or history of autoimmune diseases that may recur (e.g. systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis, etc.), or patients at high risk (such as immunosuppressive therapy required for organ transplants). Except for autoimmune hypothyroidism that requires only hormone replacement therapy or skin diseases that do not require systemic treatment;
- Patients who need to receive systemic corticosteroids (dose equivalent to > 10mg prednisone / day) or other immunosuppressive drugs within 14 days before enrollment or during the study. The use of topical or inhaled corticosteroids, or short-term (≤ 7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune and infrequent allergic diseases;
- Important organ failure or other serious diseases, including interstitial pneumonia, clinically related coronary artery disease, cardiovascular disease or myocardial infarction, congestive heart failure, unstable angina pectoris, symptomatic pericardial effusion or unstable arrhythmia within 6 months before admission;
- A history of human immunodeficiency virus infection, or other acquired, congenital immunodeficiency diseases, or a history of organ transplant or stem cell transplantation;
- Patients with active chronic hepatitis B or active hepatitis C. HBV carriers, stable hepatitis B (DNA titer ≤ 103copies / ml) and cured hepatitis C patients (HCVRNA negative) can be enrolled in the group;
- A history of severe neurological or psychiatric illness; severe infection; active disseminated intravascular coagulation or other concomitant diseases that, in the opinion of the researchers, seriously endanger the safety of patients or affect the completion of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Envafolimab combined with recombinant human endostatin and first-line chemotherapy
|
Envafolimab: 300mg day1, s.c. Q3W; Recombinant human endostatin: 210mg day1, Intravenous pump for 72 hours, Q3W; Temozolomide: 150 mg/m2 d1-5, i.v. Q3W; Cisplatin: 25 mg/m2 d1-3, i.v. Q3W. All of the above drugs were used for 6 cycles, and then Envafolimab and recombinant human endostatin continued only in patients with no progression in the first stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 2 years. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS)
Time Frame: 12 months
|
Time from the date of randomization to the date of progressive disease (PD) or death, whichever occurs first.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: 12 months
|
ORR was defined as the percentage of participants with measurable lesions achieving a Complete Response (CR; disappearance of all target lesions) or Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters) based on Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) criteria.
|
12 months
|
Disease Control Rate (DCR)
Time Frame: 12 months
|
The proportion of participants who achieves a best overall response of CR, PR or stable disease(SD).
|
12 months
|
Duration of Response (DoR)
Time Frame: 12 months
|
The time from the date that response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first.
|
12 months
|
Overall Survival (OS)
Time Frame: 12 months
|
OS is defined as the time from enrollment to death from any cause.
|
12 months
|
PD-L1 expression from the tissue and peripheral blood samples of the patients
Time Frame: baseline (When entering the group)
|
The tissue and peripheral blood samples of the patients were taken for the determination of PD-L1 expression, and the results were analyzed to find the predictive factors of prognosis or curative effect.
|
baseline (When entering the group)
|
ctDNA expression from the tissue and peripheral blood samples of the patients
Time Frame: baseline (When entering the group)
|
The tissue and peripheral blood samples of the patients were taken for the determination of ctDNA expression, and the results were analyzed to find the predictive factors of prognosis or curative effect.
|
baseline (When entering the group)
|
Adverse Events (AEs) according to CTCAE v5.0.
Time Frame: 12 months
|
Adverse Events (AEs) according to CTCAE v5.0.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zhiguo Luo, M.D, Fudan University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Endostatins
Other Study ID Numbers
- Fudan-MM003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Mucosal Melanoma
-
National Cancer Institute (NCI)RecruitingMucosal Melanoma | Anal Melanoma | Bladder Melanoma | Cervical Melanoma | Esophageal Melanoma | Gallbladder Melanoma | Mucosal Melanoma of the Head and Neck | Mucosal Melanoma of the Urinary System | Oral Cavity Mucosal Melanoma | Penile Mucosal Melanoma | Rectal Melanoma | Recurrent Mucosal Melanoma | Sinonasal... and other conditionsUnited States, Canada
-
Peking University Cancer Hospital & InstituteUnknownAdvanced Mucosal MelanomaChina
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedMetastatic Melanoma | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage III Mucosal Melanoma of the Head and Neck | Stage IVA Mucosal Melanoma of the Head and Neck | Stage IVB Mucosal Melanoma of the Head and Neck | Stage IVC Mucosal Melanoma...United States
-
Henan Cancer HospitalUnknownAdvanced Cancer | Mucosal Melanoma | Apatinib | SHR-1210China
-
Fred Hutchinson Cancer CenterAmazon.com Services LLCRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditionsUnited States
-
Viewpoint Molecular TargetingMayo ClinicCompletedMelanoma (Skin) | Melanoma Stage IV | Melanoma, Uveal | Melanoma, MucosalUnited States
-
Hoffmann-La RocheCompletedUveal Melanoma | Cutaneous Melanoma | Mucosal MelanomaSpain, United States, Belgium, Denmark, Canada, Australia
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Eye & ENT Hospital of Fudan UniversityCancer Institute and Hospital, Chinese Academy of Medical SciencesRecruitingMucosal Melanoma | Sinonasal MelanomaChina
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
Clinical Trials on Envafolimab combined with recombinant human endostatin and first-line chemotherapy
-
Anhui Chest HospitalNot yet recruitingCarcinoma, Non-Small-Cell Lung
-
Hairong LiuNot yet recruiting
-
Chongqing University Cancer HospitalNot yet recruitingNasopharyngeal Carcinoma
-
Second Xiangya Hospital of Central South UniversityEnrolling by invitationNon-small Cell Lung CancerChina
-
Qilu Hospital of Shandong UniversityRecruitingSquamous Non-small Cell Lung CancerChina
-
Sun YanPeking University; Peking University Cancer Hospital & InstituteUnknownHead and Neck NeoplasmsChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruiting
-
Simcere Pharmaceutical Co., LtdDaping Hospital and the Research Institute of Surgery of the Third Military...Unknown
-
Hebei Medical UniversityRecruitingLeptomeningeal Metastasis | Immune Checkpoint Inhibitor | EndostatinChina
-
Fujian Cancer HospitalRecruitingUntreated Advanced Non-small Cell Lung CancerChina